{
    "code": "02023388",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02023388",
    "time": "2022-01-21 06:08:14",
    "許可證字號": "衛署藥輸字第023388號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "116\/03\/01",
    "發證\/登錄日期": "91\/03\/01",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA00202338807",
    "中文品名": "脂黴素微脂粒凍晶乾粉注射劑",
    "英文品名": "AMBISOME FOR INJECTION",
    "適應症": "• 治療感染囊球菌腦膜炎的HIV患者\r\n• 治療嚴重全身性及\/ 或深部黴菌感染\r\n• 治療臟器的利時曼氏病。在免疫不全且患有臟器的利時曼氏病之患者使用\r\nAmBisome治療，在初期寄生蟲清除後仍有高復發率。\r\n• 對發燒的重度嗜中性白血球缺乏症患者可能罹患黴菌感染症之經驗療法。",
    "劑型": "247凍晶乾粉注射劑",
    "包裝": "每盒100支以下小瓶",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "AMPHOTERICIN B",
    "限制項目": "02輸　入",
    "申請商名稱": "620117L277  香港商吉立亞醫藥有限公司台灣分公司",
    "申請商地址": "臺北市信義區松仁路32號10樓之1、36號10樓之1",
    "主製造廠": [
        {
            "": "UNITED STATES",
            "製程": ""
        }
    ],
    "CCC號列": "30042000916 人用醫藥製劑，含有其他抗生素者Medicaments, containing other antibiotics, for human use",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "0812200102",
            "成分名稱": "AMPHOTERICIN B",
            "含量描述": "",
            "含量": "50.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "AmBisome脂黴素微脂粒凍晶乾粉注射劑 中文仿單-29.7x48cm-20180906-107-09-13.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02023388&Seq=008&Type=9"
        },
        {
            "title": "020233880003-102-07-12.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02023388&Seq=002&Type=8"
        }
    ]
}